A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells.

The Siglec family of cell surface receptors have emerged as attractive targets for cell-directed therapies due to their restricted expression on immune cells, endocytic properties, and ability to modulate receptor signaling. Human Siglec-8, for instance, has been identified as a therapeutic target for the treatment of eosinophil and mast cell disorders. A promising strategy to target Siglecs involves the use of liposomal nanoparticles with a multivalent display of Siglec ligands.

Regulation of Hematopoietic Cell Development and Function Through Phosphoinositides.

One of the most paramount receptor-induced signal transduction mechanisms in hematopoietic cells is production of the lipid second messenger phosphatidylinositol(3,4,5)trisphosphate (PIP) by class I phosphoinositide 3 kinases (PI3K). Defective PIP signaling impairs almost every aspect of hematopoiesis, including T cell development and function. Limiting PIP signaling is particularly important, because excessive PIP function in lymphocytes can transform them and cause blood cancers.